BRPI0413540A - moduladores gabanérgicos - Google Patents
moduladores gabanérgicosInfo
- Publication number
- BRPI0413540A BRPI0413540A BRPI0413540-7A BRPI0413540A BRPI0413540A BR PI0413540 A BRPI0413540 A BR PI0413540A BR PI0413540 A BRPI0413540 A BR PI0413540A BR PI0413540 A BRPI0413540 A BR PI0413540A
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- compounds
- gabanergic
- modulators
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
"MODULADORES GABANéRGICOS". A presente invenção refere-se ao uso de compostos de fórmula (I), sais e solvatos dos mesmos, para a preparação de um medicamento para modular os receptores GABA~ A~do subtipo<244>~ 2~. A invenção refere-se ainda a novos compostos heterocíclicos e a composições farmacêuticas contendo os ditos compostos. Além disso, a invenção refere-se ao uso de compostos de fórmula (I), sais e solvatos dos mesmos, para a preparação de um medicamento para o tratamento de um distúrbio de depressão, um distúrbio de ansiedade, um distúrbio psiquiátrico, um distúrbio de aprendizagem ou cognitivo, um distúrbio do sono, um distúrbio convulsivo ou epiléptico ou dores.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49517903P | 2003-08-14 | 2003-08-14 | |
US57438404P | 2004-05-25 | 2004-05-25 | |
PCT/EP2004/008767 WO2005016892A1 (en) | 2003-08-14 | 2004-08-05 | Gabanergic modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413540A true BRPI0413540A (pt) | 2006-10-10 |
Family
ID=34198028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413540-7A BRPI0413540A (pt) | 2003-08-14 | 2004-08-05 | moduladores gabanérgicos |
Country Status (14)
Country | Link |
---|---|
US (1) | US7365211B2 (pt) |
EP (1) | EP1656353B1 (pt) |
JP (1) | JP2007502257A (pt) |
KR (1) | KR100742014B1 (pt) |
AR (1) | AR045255A1 (pt) |
AT (1) | ATE456558T1 (pt) |
AU (1) | AU2004265101B2 (pt) |
BR (1) | BRPI0413540A (pt) |
CA (1) | CA2535406A1 (pt) |
DE (1) | DE602004025354D1 (pt) |
MX (1) | MXPA06001660A (pt) |
RU (1) | RU2376292C2 (pt) |
TW (1) | TW200524878A (pt) |
WO (1) | WO2005016892A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
MX2007000791A (es) * | 2004-08-03 | 2007-03-23 | Wyeth Corp | Indazoles utiles en el tratamiento de enfermedades cardiovasculares. |
CA2644910C (en) | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
MX2008012952A (es) * | 2006-04-11 | 2008-10-15 | Hoffmann La Roche | Moduladores heterociclicos del receptor selectivo del subtipo alfa de gaba. |
EP2097401A1 (en) * | 2006-12-22 | 2009-09-09 | F. Hoffmann-Roche AG | Processes for the preparation of (3r, 4r) -n- (4 -chlorophenyl) -1- (2, 2-difluoroethyl) -n' - [2-fluoro-4- (2-oxo-1 (2h) -pyridinyl) phenyl]-3, 4-pyrrolidinedicarboxamide |
AU2008254279B2 (en) * | 2007-05-15 | 2013-03-14 | Aventis Agriculture | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
SG10201703698QA (en) | 2008-11-14 | 2017-06-29 | Merial Inc | Enantiomerically enriched aryloazol- 2 -yl cyanoethylamino paraciticidal compounds |
ES2481715T3 (es) | 2009-02-06 | 2014-07-31 | Janssen Pharmaceuticals, Inc. | Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa |
ES2431619T3 (es) | 2009-05-07 | 2013-11-27 | Janssen Pharmaceuticals, Inc. | Derivados de indazol y aza-indazol sustituidos como moduladores de gamma-secretasa |
KR20120050450A (ko) | 2009-07-15 | 2012-05-18 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체 |
BR112012017310A2 (pt) | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | derivados de triazol substituídos como moduladores de gama secretase |
JP2013530180A (ja) * | 2010-06-16 | 2013-07-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | アリール置換インドールおよびその使用 |
BR112013023984A2 (pt) | 2011-03-24 | 2016-09-13 | Cellzome Ltd | derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase |
EA023045B1 (ru) | 2011-07-15 | 2016-04-29 | Янссен Фармасьютикалз, Инк. | Новые замещенные производные индола в качестве модуляторов гамма-секретазы |
US9181245B2 (en) | 2012-05-16 | 2015-11-10 | Janssen Pharmaceuticals, Inc. | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease |
JP2014034523A (ja) * | 2012-08-07 | 2014-02-24 | Manac Inc | モノまたはジハロゲノピリジルアミン類の製造方法 |
US8822689B2 (en) | 2012-09-19 | 2014-09-02 | Merial Limited | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
US9296746B2 (en) | 2012-10-16 | 2016-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP2953949B1 (en) | 2012-12-20 | 2016-09-28 | Janssen Pharmaceutica NV | Novel tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
KR102171710B1 (ko) | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
TW202000666A (zh) | 2018-02-27 | 2020-01-01 | 美商英塞特公司 | 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
WO2019200061A1 (en) * | 2018-04-11 | 2019-10-17 | The General Hospital Corporation | Anesthetic compounds |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
CA3105721A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
US11911364B2 (en) | 2018-09-25 | 2024-02-27 | Pepticom Ltd. | Positive allosteric modulators of GABAA receptor |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
WO2022006541A1 (en) * | 2020-07-02 | 2022-01-06 | Praxis Precision Medicines, Inc. | Methods for the treatment of adjustment disorder |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9801538D0 (en) | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
GB0008696D0 (en) * | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic agents |
AU2001267963A1 (en) * | 2000-06-30 | 2002-01-08 | Light Eye Developments Limited | Improved dynamo |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
AU2001287114A1 (en) * | 2000-09-06 | 2002-03-22 | Neurogen Corporation | Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor |
BR0316950A (pt) * | 2002-12-02 | 2006-01-17 | Hoffmann La Roche | Derivados de indazol como antagonistas de crf |
-
2004
- 2004-08-05 BR BRPI0413540-7A patent/BRPI0413540A/pt not_active IP Right Cessation
- 2004-08-05 MX MXPA06001660A patent/MXPA06001660A/es active IP Right Grant
- 2004-08-05 AU AU2004265101A patent/AU2004265101B2/en not_active Ceased
- 2004-08-05 EP EP04763813A patent/EP1656353B1/en not_active Not-in-force
- 2004-08-05 DE DE602004025354T patent/DE602004025354D1/de active Active
- 2004-08-05 WO PCT/EP2004/008767 patent/WO2005016892A1/en active Application Filing
- 2004-08-05 KR KR1020067002966A patent/KR100742014B1/ko not_active IP Right Cessation
- 2004-08-05 RU RU2006107438/04A patent/RU2376292C2/ru not_active IP Right Cessation
- 2004-08-05 JP JP2006522959A patent/JP2007502257A/ja active Pending
- 2004-08-05 AT AT04763813T patent/ATE456558T1/de not_active IP Right Cessation
- 2004-08-05 CA CA002535406A patent/CA2535406A1/en not_active Abandoned
- 2004-08-11 TW TW093124065A patent/TW200524878A/zh unknown
- 2004-08-11 US US10/916,073 patent/US7365211B2/en not_active Expired - Fee Related
- 2004-08-12 AR ARP040102881A patent/AR045255A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007502257A (ja) | 2007-02-08 |
RU2006107438A (ru) | 2007-09-20 |
CA2535406A1 (en) | 2005-02-24 |
AU2004265101A1 (en) | 2005-02-24 |
EP1656353A1 (en) | 2006-05-17 |
WO2005016892A1 (en) | 2005-02-24 |
KR100742014B1 (ko) | 2007-07-23 |
AR045255A1 (es) | 2005-10-19 |
ATE456558T1 (de) | 2010-02-15 |
MXPA06001660A (es) | 2006-04-28 |
KR20060037440A (ko) | 2006-05-03 |
DE602004025354D1 (de) | 2010-03-18 |
US20050101614A1 (en) | 2005-05-12 |
AU2004265101B2 (en) | 2009-06-11 |
US7365211B2 (en) | 2008-04-29 |
RU2376292C2 (ru) | 2009-12-20 |
TW200524878A (en) | 2005-08-01 |
EP1656353B1 (en) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413540A (pt) | moduladores gabanérgicos | |
BR0205829A (pt) | Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas | |
HUP0400365A2 (hu) | 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
MXPA04007470A (es) | Piridinonas sustituidas. | |
BRPI0412219A (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença | |
HUP0303037A2 (hu) | Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
BR0312758A (pt) | Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6 | |
HUP0402310A2 (hu) | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
DE59409312D1 (de) | Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten | |
BR0110703A (pt) | Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos | |
ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
HUP0401086A2 (hu) | 4-[(Fenil-piperazinil)-metil]-benzamid-származékok és alkalmazásuk fájdalom, szorongás vagy gasztrointesztinális zavarok kezelésére szolgáló gyógyszerkészítmények előállítására és eljárás a vegyületek előállítására | |
BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
BR0215151A (pt) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
ATE457027T1 (de) | Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht | |
BR0314302A (pt) | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) | |
HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
PT779284E (pt) | Novos derivados de 2-naftamidas e suas aplicacoes terapeuticas como agonistas dos receptores d3 | |
BR0210285A (pt) | Utilização de um composto, composto e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |